Last reviewed · How we verify
NCT05708716
Diet and Cognitive Training in Hematologic Cancer Survivors
NA trial testing Modified ketogenic diet using an exogenous ketogenic formula in Cognitive Impairment in 80 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | University of Alabama at Birmingham |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 80 |
| Start date | 22 November 2022 |
| Primary completion | 31 December 2026 |
| Estimated completion | 30 April 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Modified ketogenic diet using an exogenous ketogenic formula
- Online cognitive training
Conditions studied
- Cognitive Impairment — all drugs for Cognitive Impairment →
- Hematologic Malignancy — all drugs for Hematologic Malignancy →
Sponsor
University of Alabama at Birmingham
Who can join
21 and older, any sex, with Cognitive Impairment or Hematologic Malignancy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to examine feasibility of a cognitive intervention program in blood cancer survivors. The main questions it aims to answer are: * is it feasible to combine a ketogenic diet supplementation and online cognitive training in an intervention program * will patients using the combined intervention program have improved cognitive functioning compared to those who don't use it * how long will the intervention programs effects last Participants randomized to the intervention arm will consume an exogenous ketogenic supplementation and use an online cognitive training program for 12 weeks, while waitlist arm functions as a control group and will receive the online cognitive training only after a wait period of 12 weeks. Researchers will compare the intervention and waitlist control groups to see if the intervention improves cognitive functioning.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05708716
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cognitive Impairment
Currently open trials in the same condition.
- NCT07504276 — Tele-Rehabilitation vs Conventional Rehabilitation for Cognitive Improvement in Stroke Survivors. · NA · recruiting
- NCT07396779 — Cognitive Task-Based Walking Effects on Cognition, Mood, Sleep, and Quality of Life in Older Adults With Brain Fog · NA · active not recruiting
- NCT07084831 — A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment i · Phase 3 · recruiting
- NCT07125378 — Living Independence Through Functional Training · Phase 1, PHASE2 · recruiting
- NCT07268079 — Validation of the VIRADIA App for Neurological and Cognitive Diagnostics in Virtual Reality · recruiting
Other University of Alabama at Birmingham trials
Trials by the same sponsor.
- NCT04922229 — Comparative Effectiveness in the Management of Irreversible Pulpitis · NA · not yet recruiting
- NCT05060380 — Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis · NA · withdrawn
- NCT04768777 — Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis · NA · not yet recruiting
- NCT06320951 — VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine · Phase 2 · not yet recruiting
- NCT07564934 — Leveraging Extended Reality Exergaming and Telehealth to Improve Physical Activity and Health in Children With Disabilit · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05708716 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Alabama at Birmingham
- Last refreshed: 17 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05708716.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing